Here's why RBC Capital lifted the S&P 500 year-end price target
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
How major US stock indexes fared Monday, 7/14/2025
U.S. stock indexes held near their records following President Donald Trump's latest updates to his tariffs, as speculation continues that he may ultimately back down on them. The S&P 500 edged up by 0.1% Monday. The Dow Jones Industrial Average added 0.2%, and the Nasdaq composite rose 0.3%. Stock indexes fell in Europe but were mixed elsewhere after Trump announced 30% tariffs on goods from Mexico and the European Union. They won't take effect until Aug. 1, which leaves time for more negotiations. Treasury yields held steady in the bond market, while bitcoin rallied at the start of Washington's 'Crypto Week.' On Monday: The S&P 500 rose 8.81 points, or 0.1%, to 6,268.56. The Dow Jones Industrial Average rose 88.14 points, or 0.2%, to 44,459.65. The Nasdaq composite rose 54.80 points, or 0.3%, to 20,640.33. The Russell 2000 index of smaller companies rose 14.90 points, or 0.7%, to 2,249.73. For the year: The S&P 500 is up 386.93 points, or 6.6%. The Dow is up 1,915.43 points, or 4.5%. The Nasdaq is up 1,329.53 points, or 6.9%. The Russell 2000 is up 19.57 points, or 0.9%.
Los Angeles Times
an hour ago
- Los Angeles Times
Wall Street holds near its record amid doubts about Trump's tariffs
Stock indexes hung near their records on Monday following President Donald Trump's latest updates to his tariffs, as speculation continues on Wall Street that he may ultimately back down on them. The S&P 500 edged up by 0.1% to pull within 0.2% of its all-time high set on Thursday. The Dow Jones Industrial Average added 88 points, or 0.2%, and the Nasdaq composite climbed 0.3% to set a record. Stock indexes elsewhere around the world were mixed in their first trading after Trump announced plans over the weekend for 30% tariffs on goods from Mexico and the European Union. They won't take effect until Aug. 1, the same deadline that Trump announced last week for updated tax rates on imports from Japan, South Korea and a dozen other countries. The latest postponements for Trump's tariffs allow more time for him to reach trade deals with other countries that could lower the tariff rates and prevent pain for international trade. They also feed into speculation that Trump may ultimately back down on his tariffs if they end up creating too much damage for the economy and for financial markets. If Trump were to enact all his proposed tariffs on Aug. 1, they would raise the risk of a recession. That would not only hurt U.S. voters but also raise the pressure on the U.S. government's debt level relative to the economy's size, particularly after Washington approved big tax cuts that will add to the deficit. 'We therefore believe that the administration is using this latest round of tariff escalation to maximize its negotiating leverage and that it will ultimately de-escalate, especially if there is a new bout of heightened bond and stock market volatility,' according to Ulrike Hoffmann-Burchardi, global head of equities at UBS Global Wealth Management. 'As usual, there are many conditions and clauses that can get these rates reduced,' said Brian Jacobsen, chief economist at Annex Wealth Management. 'That's probably why the market might not like the tariff talk, but it's not panicking about it either.' For the time being, all the uncertainty around tariffs could help keep markets unsteady. This upcoming week has several potential flashpoints that could shake things. On Tuesday will come the latest reading on inflation across the United States. Economists expect it to show inflation accelerated to 2.6% last month from 2.4% in May. Companies are also lining up to report how they performed during the spring. JPMorgan Chase and several other huge banks will report their latest quarterly results on Tuesday, followed by Johnson & Johnson on Wednesday and PepsiCo on Thursday. Fastenal, a distributor of industrial and construction supplies, on Monday reported a stronger profit for the latest quarter than analysts expected. Its stock rose 4.2%, though it also said that market conditions remain sluggish. Shares of Kenvue rose 2.2% after the former division of Johnson & Johnson said CEO Thibaut Mongon is stepping down. Kenvue, the maker of Listerine and Band-Aid brands, is in the midst of a strategic review of its options, 'including ways to simplify the company's portfolio and how it operates,' according to Larry Merlo, the board's chair. Waters slumped 13.8% after saying it had agreed to merge with Becton, Dickinson and Co.'s biosciences and diagnostic solutions business in a deal valued at roughly $17.5 billion. All told, the S&P 500 rose 8.81 points to 6,268.56. The Dow Jones Industrial Average added 88.14 to 44,459.65, and the Nasdaq composite climbed 54.80 to 20,640.33 to top its last all-time high set on Thursday. In the bond market, Treasury yields held relatively steady. The yield on the 10-year Treasury slipped to 4.42% from 4.43% late Friday. In stock markets abroad, indexes fell across much of Europe. Germany's DAX lost 0.4%, and France's CAC 40 fell 0.3%. But indexes rose 0.8% in South Korea and 0.3% in Hong Kong. Chinese shares advanced after the government reported that exports rose last month as a truce in a tariff war prompted a surge in orders ahead of the Aug. 1 deadline for reaching a new trade deal with Washington. Some of the biggest moves in financial markets were for crypto, where bitcoin continues to set records. This upcoming week is 'Crypto Week' in Washington, where Congress will consider several bills to 'make America the crypto capital of the world.' Choe writes for the Associated Press.
Yahoo
an hour ago
- Yahoo
Why Moderna (MRNA) Stock Is Falling Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its list of top short ideas for the second half of 2025. The investment bank's negative outlook stems from concerns over Moderna's continued cash burn, potential regulatory headwinds, and a lack of clear growth drivers in the near term. A "short" is a trading strategy where an investor bets that a stock's price will fall. While the stock has seen a recent bounce, it remains down significantly for the year. JPMorgan's analysts do not foresee a major rebound for the biotechnology firm. This assessment comes despite some recent positive news for the company, including an expanded FDA approval for its COVID-19 vaccine, Spikevax, for high-risk children. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Moderna? Access our full analysis report here, it's free. Moderna's shares are extremely volatile and have had 51 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 3% on the news that the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. Moderna is down 21.4% since the beginning of the year, and at $33.01 per share, it is trading 73.6% below its 52-week high of $125.14 from July 2024. Investors who bought $1,000 worth of Moderna's shares 5 years ago would now be looking at an investment worth $439.83. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
